Resverlogix Corp. (RVX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Resverlogix Corp. (RVX) has a cash flow conversion efficiency ratio of 0.010x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-925.52K ≈ $-669.51K USD) by net assets (CA$-94.12 Million ≈ $-68.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see RVX stock market capitalisation for the company's overall valuation and market capitalisation.
Resverlogix Corp. - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Resverlogix Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Resverlogix Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Resverlogix Corp. ranked by their cash flow conversion efficiency. Explore Resverlogix Corp. (RVX) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pantera Silver Corp
V:PNTR
|
-0.027x |
|
Alpcot Holding AB Series B
ST:ALPCOT-B
|
-0.159x |
|
Ulima Nitra PT
JK:UNIQ
|
0.040x |
|
Nord Insuretech Group AB
ST:NORDIG
|
0.533x |
|
KPX Lifescience.Co.Ltd
KQ:114450
|
0.095x |
|
Panca Global Securities Tbk
JK:PEGE
|
-0.129x |
|
Hamashbir 365 Holdings Ltd
TA:MSBI
|
0.659x |
|
Fuji Finance Indonesia Tbk PT
JK:FUJI
|
0.122x |
Annual Cash Flow Conversion Efficiency for Resverlogix Corp. (2001–2025)
The table below shows the annual cash flow conversion efficiency of Resverlogix Corp. from 2001 to 2025. View Resverlogix Corp. stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$-88.80 Million ≈ $-64.24 Million |
CA$-3.73 Million ≈ $-2.69 Million |
0.042x | -11.77% |
| 2024-12-31 | CA$-81.73 Million ≈ $-59.13 Million |
CA$-3.89 Million ≈ $-2.81 Million |
0.048x | +35.51% |
| 2023-12-31 | CA$-74.47 Million ≈ $-53.87 Million |
CA$-2.61 Million ≈ $-1.89 Million |
0.035x | -41.26% |
| 2022-12-31 | CA$-59.28 Million ≈ $-42.88 Million |
CA$-3.54 Million ≈ $-2.56 Million |
0.060x | -55.43% |
| 2021-12-31 | CA$-59.87 Million ≈ $-43.31 Million |
CA$-8.02 Million ≈ $-5.80 Million |
0.134x | +121392.30% |
| 2020-12-31 | CA$-39.90 Million ≈ $-28.86 Million |
CA$-4.40K ≈ $-3.18K |
0.000x | -99.96% |
| 2019-12-31 | CA$-64.11 Million ≈ $-46.38 Million |
CA$-17.34 Million ≈ $-12.55 Million |
0.271x | +15.07% |
| 2018-12-31 | CA$-207.72 Million ≈ $-150.26 Million |
CA$-48.83 Million ≈ $-35.33 Million |
0.235x | -21.73% |
| 2017-12-31 | CA$-83.68 Million ≈ $-60.53 Million |
CA$-25.13 Million ≈ $-18.18 Million |
0.300x | +34.58% |
| 2016-12-31 | CA$-101.57 Million ≈ $-73.47 Million |
CA$-22.67 Million ≈ $-16.40 Million |
0.223x | -41.21% |
| 2015-12-31 | CA$-56.43 Million ≈ $-40.82 Million |
CA$-21.42 Million ≈ $-15.50 Million |
0.380x | +229.32% |
| 2014-12-31 | CA$-73.73 Million ≈ $-53.33 Million |
CA$-8.50 Million ≈ $-6.15 Million |
0.115x | -44.80% |
| 2013-12-31 | CA$-63.22 Million ≈ $-45.73 Million |
CA$-13.20 Million ≈ $-9.55 Million |
0.209x | -78.75% |
| 2012-12-31 | CA$-29.50 Million ≈ $-21.34 Million |
CA$-29.00 Million ≈ $-20.98 Million |
0.983x | +111.21% |
| 2011-12-31 | CA$2.74 Million ≈ $1.98 Million |
CA$-24.03 Million ≈ $-17.38 Million |
-8.766x | -95.92% |
| 2010-12-31 | CA$4.30 Million ≈ $3.11 Million |
CA$-19.24 Million ≈ $-13.92 Million |
-4.474x | -8.91% |
| 2009-12-31 | CA$4.46 Million ≈ $3.23 Million |
CA$-18.34 Million ≈ $-13.26 Million |
-4.108x | -266.55% |
| 2008-12-31 | CA$11.61 Million ≈ $8.40 Million |
CA$-13.01 Million ≈ $-9.41 Million |
-1.121x | +68.96% |
| 2007-12-31 | CA$5.44 Million ≈ $3.94 Million |
CA$-19.65 Million ≈ $-14.21 Million |
-3.611x | -137.13% |
| 2006-12-31 | CA$-1.02 Million ≈ $-738.42K |
CA$-9.93 Million ≈ $-7.18 Million |
9.724x | +1749.37% |
| 2005-12-31 | CA$7.48 Million ≈ $5.41 Million |
CA$-4.41 Million ≈ $-3.19 Million |
-0.590x | -166.26% |
| 2004-12-31 | CA$9.84 Million ≈ $7.12 Million |
CA$-2.18 Million ≈ $-1.58 Million |
-0.221x | +35.03% |
| 2003-12-31 | CA$2.60 Million ≈ $1.88 Million |
CA$-885.04K ≈ $-640.23K |
-0.341x | +29.20% |
| 2002-12-31 | CA$942.21K ≈ $681.58K |
CA$-453.56K ≈ $-328.10K |
-0.481x | -1038.52% |
| 2001-12-31 | CA$259.64K ≈ $187.82K |
CA$-10.98K ≈ $-7.94K |
-0.042x | -- |
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID… Read more